TransCode Therapeutics Advances Clinical Trial with New Dose for TTX-MC138 in Patients TransCode Therapeutics has completed dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, showing promising early safety results and pharmacokinetic profiles.

TransCode Therapeutics Advances Clinical Trial with New Dose for TTX-MC138 in Patients #United_States #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_RNAZ